+ All Categories
Home > Documents > BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Date post: 23-Dec-2015
Category:
Upload: gordon-roberts
View: 215 times
Download: 0 times
Share this document with a friend
Popular Tags:
19
BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation
Transcript
Page 1: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

BIOSIGNAL Pty LtdBIOSIGNAL Pty Ltd

Tove Ringbom Lotta Ekman

Business Plan Evaluation

Page 2: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

What is a biofilm?What is a biofilm?

• Biofilms are colonies of living micro-organisms (e.g., bacteria, fungi, algae, and/or protozoa) growing on any surface (e.g. metals, plastics, tissue, soil particles, teeth, and so forth)

Page 3: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

BiofilmsBiofilms

Page 4: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

How are biofilms formed?How are biofilms formed?

http://www.crca.asn.au/activities/2002/conference/Plenary2/Jasjit/Biofilm_Jasjit.swf

Page 5: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Biofilm infectionsBiofilm infections

• cause dental cavities, gum disease, as well as ear-, heart- and lung infections

• Biofilms also form on contact lenses and on intrauterine birth control devises

• Biofilms on the inner surfaces of medical equipment (catheters) hospital infections

Page 6: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.
Page 7: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

The InnovationThe Innovation

The seaweed (Delisea pulchra) remains slime-free due to the production of furanones

Biosignal has patented synthetic analogs of these furanones

Furanones prevent bacteria from attaching to surfaces no biofilm formation

Page 8: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

http://www.crca.asn.au/activities/2002/conference/Plenary2/Jasjit/PreventionJasjit.swf

Page 9: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Business OpportunityBusiness Opportunity

• By attaching furanones to polymers, biofilm formation could be prevented in

1) marine and agriculture usages

2) bound to polymer coatings

3) in implantable medical devices such as catheters

Page 10: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Evaluating the Business PlanEvaluating the Business Plan

• Plan dated December 6th 2000

• Clear purpose stated

- $5.3 million to expand R&D

- to hire an experienced chief executive officer

- raise money in order to register its patented compounds with the EPA and FDA

Page 11: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

ManagementManagement

• Biosignal lacks a CEO at the moment

Demanding requirements

• An experienced polymer chemist must be hired

• Professors Kjellberg & Steinberg possess scientific experience in the field of marine biology and microbiology

• GM Rohan McDougall

Page 12: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Market AssessmentMarket Assessment

• Biosignal found six different areas of interest:- Household cleaners - Oral care - Contact lens solutions - Anti-foulant in marine paint - Commercial farming applications - Biomaterials

Page 13: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

RisksRisks

• Biosignals technology may fail to deliver on its early promises

• The safety risks to patients and to the environment are not known at this point

Page 14: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Segment for first market entry Segment for first market entry

• Catheter market

• The medical grade polymers demonstrate the greatest revenue opportunity of the six different options

• The catheter market is growing rapidly, as is the total biomaterials market

• Reason for choosing the segment: the disposable catheter is a relatively simple device

ambition is to move to more technologically advanced medical devices at a later stage

Page 15: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Competitor InformationCompetitor Information

• 156 companies operate on the global catheter market today

• Several multinational polymer giants operate in this field

• PROBLEM: big organizations such as hospitals generally make group purchases and catheters are often priced as a part of a bundle of products

Page 16: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

CollaborationsCollaborations

• Biosignal gets office space and lab space support from UNSW and the two Research Directors are employed part time by UNSW

• A cooperation project to manufacture Biosignal’s product with an “American specialty chemical manufacturer”

• Multinational partners are key success factors for this venture

Page 17: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

FinancialsFinancials

• Biosignal has established connections to a few companies

• Estimated personnel expenses may not be big enough

• R&D expenses ought to rise as time goes by - Biosignal is aware

Page 18: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

Our conclusion Our conclusion

• Start with any of the applications that are outside the human body to get cash flow

• The biomaterials market is very tricky

• Get experience in manufacturing, sales and running a business before entering the markets that require FDA approval

Page 19: BIOSIGNAL Pty Ltd Tove Ringbom Lotta Ekman Business Plan Evaluation.

THANKYOU!

THANKYOU!


Recommended